Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts

Hope Rugo • 29 Sep 2019
ESMO 2019
Breast Cancer Alpelisib Fulvestrant
SOLAR-1

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Hope Rugo, MD, FASCO, UCSF Comprehensive Cancer Center, San Diego, CA, discusses the SOLAR-1 trial (NCT02437318). This trial is investigating alpelisib with fulvestrant for the treatment of HR+/HER2- advanced breast cancer. Here, Dr Rugo discusses the management and time course of key adverse events of special interest.

More from Hope Rugo

3:24
What to look forward to in breast cancer at ASCO 2023
Hope Rugo • 12 May 2023
6:33
Detailed safety analysis from the DESTINY-Breast04 trial
Hope Rugo • 12 May 2023
4:01
KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs
Hope Rugo • 12 May 2023
4:04
Hot topics in breast cancer in 2023 - what is coming next?
Hope Rugo • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals